Koskinas KC, Van Craenenbroeck EM, Antoniades C, Blüher M, Gorter TM, Hanssen H, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur Heart J. 2024;45:4063–98.
Google Scholar
Ruperez C, Madeo F, De Cabo R, Kroemer G, Abdellatif M. Obesity accelerates cardiovascular ageing. Eur Heart J. 2025;ehaf216.
Leggat J, Bidault G, Vidal-Puig A. Lipotoxicity: a driver of heart failure with preserved ejection fraction? Clin Sci Lond Engl. 1979;2021(135):2265–83.
Abdellatif M, Kroemer G. Heart failure with preserved ejection fraction: an age-related condition. J Mol Cell Cardiol. 2022;S0022–2828(22):00052–9.
Fuerlinger A, Stockner A, Sedej S, Abdellatif M. Caloric restriction and its mimetics in heart failure with preserved ejection fraction: mechanisms and therapeutic potential. Cardiovasc Diabetol. 2025;24:21.
Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res. 2023;118:3434–50.
Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2016;315:36–46.
Google Scholar
O’Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet Lond Engl. 2018;392:637–49.
Wang A, Speakman JR. Potential downsides of calorie restriction. Nat Rev Endocrinol. 2025;21:427–40.
Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, et al. Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2016;13:119–26.
Google Scholar
Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrøm SZ, Davies MJ, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet Lond Engl. 2024;403:1635–48.
Google Scholar
Stockner A, Degli Innocenti M, Verma D, T Schmid S, Fuerlinger A, Varghese A, et al. Inhibition of Adipose Tissue Lipolysis Treats Obesity-Related HFpEF. Circ Res. 2025;136:1519–22.
Mayer N, Schweiger M, Romauch M, Grabner GF, Eichmann TO, Fuchs E, et al. Development of small-molecule inhibitors targeting adipose triglyceride lipase. Nat Chem Biol. 2013;9:785–7.
Google Scholar
Takahara S, Ferdaoussi M, Srnic N, Maayah ZH, Soni S, Migglautsch AK, et al. Inhibition of ATGL in adipose tissue ameliorates isoproterenol-induced cardiac remodeling by reducing adipose tissue inflammation. Am J Physiol Heart Circ Physiol. 2021;320:H432–46.
Google Scholar
Lettieri Barbato D, Tatulli G, Aquilano K, Ciriolo MR. Inhibition of age-related cytokines production by ATGL: a mechanism linked to the anti-inflammatory effect of resveratrol. Mediators Inflamm. 2014;2014: 917698.
Dixon ED, Claudel T, Nardo AD, Riva A, Fuchs CD, Mlitz V, et al. Inhibition of ATGL alleviates MASH via impaired PPARα signalling that favours hydrophilic bile acid composition in mice. J Hepatol. 2025;82:658–75.
Google Scholar
Packer M. Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium. J Am Coll Cardiol. 2018;71:2360–72.
Google Scholar
Schweiger M, Romauch M, Schreiber R, Grabner GF, Hütter S, Kotzbeck P, et al. Pharmacological inhibition of adipose triglyceride lipase corrects high-fat diet-induced insulin resistance and hepatosteatosis in mice. Nat Commun. 2017;8:14859.
Google Scholar
Abdellatif M, Sedej S. Cardiovascular benefits of intermittent fasting. Cardiovasc Res. 2020;116:e36–8.
Google Scholar
Emont MP, Jacobs C, Essene AL, Pant D, Tenen D, Colleluori G, et al. A single-cell atlas of human and mouse white adipose tissue. Nature. 2022;603:926–33.
Google Scholar
Olga L, Bobeldijk-Pastorova I, Bas RC, Seidel F, Snowden SG, Furse S, et al. Lipid profiling analyses from mouse models and human infants. STAR Protoc. 2022;3: 101679.
Google Scholar
Grabner GF, Guttenberger N, Mayer N, Migglautsch-Sulzer AK, Lembacher-Fadum C, Fawzy N, et al. Small-Molecule Inhibitors Targeting Lipolysis in Human Adipocytes. J Am Chem Soc. 2022;144:6237–50.
Google Scholar
Sedej S, Abdellatif M. Metabolic therapy for managing heart failure with preserved ejection fraction. J Mol Cell Cardiol. 2022;168:68–9.
Google Scholar
Abdellatif M, Trummer-Herbst V, Koser F, Durand S, Adão R, Vasques-Nóvoa F, et al. Nicotinamide for the treatment of heart failure with preserved ejection fraction. Sci Transl Med. 2021;13:eabd7064.
Abdellatif M, Vasques-Nóvoa F, Trummer-Herbst V, Durand S, Koser F, Islam M, et al. Autophagy is required for the therapeutic effects of the NAD+ precursor nicotinamide in obesity-related heart failure with preserved ejection fraction. Eur Heart J. 2025;ehaf062.